Lexicon Pharmaceuticals, Inc., a biopharmaceutical company operating within the health care sector, recently participated in the 44th Annual J.P. Morgan Healthcare Conference, as announced on January 7, 2026, by Globenewswire.com. The company, headquartered in The Woodlands, United States, specializes in developing treatments for a range of health conditions, including diabetes, obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders, and ophthalmic disease.
As of the latest market close on January 7, 2026, Lexicon Pharmaceuticals’ share price was $1.17, a slight decrease from the previous day’s closing price of $1.18. Over the past year, the stock has experienced significant volatility, with a 52-week low of $0.28 on March 2, 2025, and a 52-week high of $1.66 on October 9, 2025. The company is listed on the Nasdaq stock exchange under the ticker symbol LXCN.
Despite its active participation in industry events, Lexicon Pharmaceuticals reported no new developments on January 7, 2026. The company’s financial metrics reflect its current market position, with a price-to-earnings (P/E) ratio of -6.16, indicating negative earnings. Additionally, the price-to-book (P/B) ratio stands at 3.44772, suggesting that the company’s market valuation is approximately three-and-a-half times its book value.
Founded in 2000, Lexicon Pharmaceuticals has been publicly traded since its Initial Public Offering (IPO) on April 7, 2000. The company’s market capitalization is currently valued at approximately $425.18 million USD. For further information, stakeholders and interested parties can visit the company’s website at www.lexpharma.com .
